Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|10056||ETCTN||A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma||Adult CIRB - Early Phase Emphasis||Available to Open|
|10050||ETCTN||A Phase II Study of Selumetinib (AZD6244) for the Treatment of Advanced Pancreas Cancer harboring KRAS G12R Mutations||Adult CIRB - Early Phase Emphasis||Completed|
|10042||ETCTN||A Phase II trial of AZD9291 (osimertinib) with or without bevacizumab in patients with EGFR mutation positive NSCLC and brain metastases||Adult CIRB - Early Phase Emphasis||Available to Open|
|10031||ETCTN||A Phase 1 Study of PARP inhibitor olaparib and HSP90 inhibitor AT13387 for treatment of advanced solid tumors with expansion in patients with recurrent epithelial ovarian; fallopian tube; peritoneal cancer or recurrent triple-negative breast cancer||Adult CIRB - Early Phase Emphasis||Available to Open|
|10030||ETCTN||A phase 1 study of blinatumomab in combination with checkpoint inhibitor(s) of PD-1 (nivolumab) or both PD-1 (nivolumab) and CTLA-4 (ipilimumab) in patients with poor-risk; relapsed or refractory CD19+ precursor B-lymphoblastic leukemia||Adult CIRB - Early Phase Emphasis||Available to Open|
|10026||ETCTN||A Phase 1 Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid||Adult CIRB - Early Phase Emphasis||Available to Open|
|10021||ETCTN||A Phase 2 Study of MEDI4736(durvalumab) and Tremelimumab Alone or in Combination with High or Low-Dose Radiation in Metastatic Colorectal and NSCLC||Adult CIRB - Early Phase Emphasis||Available to Open|
|10020||ETCTN||A Phase II Multiple-Arm; Open-Label; Randomized Study of PARP inhibition (veliparib; ABT-888) and Anti-PD-L1 Therapy (atezolizumab; MPDL3280A) Either alone or in Combination in Homologous DNA Repair (HDR) Deficient Triple Negative Breast Cancer (TNBC)||Adult CIRB - Early Phase Emphasis||Available to Open|
|10017||ETCTN||A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian Cancer||Adult CIRB - Early Phase Emphasis||Available to Open|
|10015||ETCTN||A Non-Randomized; Open-Label; Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid Hemangioendothelioma||Adult CIRB - Early Phase Emphasis||Available to Open|